Animal Model Market

Market Size (2026)
USD 2.1 Bn
Forecast (2036)
USD 3.8 Bn
CAGR (2026 to 2036)
6.1%

How big is the Animal Model Market in 2026?

The Animal Model Market is projected to reach USD 3.8 billion by 2036, and FMI estimates its 2026 value at USD 2.1 billion. That implies a 6.1% CAGR over 2026 to 2036. The market was valued at USD 2.0 billion in 2025. Revenue is expected to grow even as animal use declines in major research countries. Great Britain recorded 2.54 million procedures in 2025, the lowest count under its 1986 Act.

The difference comes from mix. Value is shifting towards genetically altered and humanized strains, which command a premium over standard stock. In France, genetically altered animals accounted for 50.0% of the 2.04 million scientific animal uses recorded in 2024. Japanese sales of genetically modified mice rose 5.7% in the year to March 2025 while total mouse sales fell 4.9%.

Animal Model Market Value Analysis chart showing growth from USD 2.1 billion in 2026 to USD 3.8 billion by 2036 at a CAGR of 6.1%
Animal Model Market Value Analysis

Non-animal methods are advancing, but regulators still require validation before they replace a defined study. FDA draft guidance issued in March 2026 sets validation principles that a new method must meet. Replacement policy remains the main limitation, and large suppliers already expect pressure on model revenue. Charles River's research models segment grew 2.0% to USD 846.1 million in 2025, yet the company guides it to a mid-single-digit decline in 2026. Demand over the forecast period will depend on drug development activity and on how quickly regulators accept replacement methods.

Key Market Trends & Insights

  • Regulators are writing the validation rules that allow alternatives to replace defined animal studies. FDA draft guidance issued on 18 March 2026 sets four validation principles for new approach methods, including context of use and human biological relevance. The agency had already proposed reducing monkey testing for certain monoclonal antibodies in December 2025. Large-animal safety studies therefore face the earliest substitution.
  • Engineered strains account for a growing part of mouse spending. In France, mice made up 94.0% of the genetically altered animals used in 2024. In Great Britain, procedures to create and breed genetically altered animals rose 1.0% in 2025 while experimental procedures fell 8.0%. Each new humanized line raises the value of an order without raising animal numbers, and strain design depends on tools covered in the gene editing tools market.
  • Model suppliers are adding non-animal methods to their portfolios to retain sponsors as method mix changes. The Jackson Laboratory now pairs its mouse genetics resources with stem cell and computational models. Crown Bioscience joined the Critical Path Institute's NAMs Developer Coalition in July 2026 to help qualify organoid and patient-derived methods. Suppliers with both capabilities can therefore hold sponsor budgets as individual studies move to alternatives.

Regional Highlights

  • In North America, federal policy is shifting research funding towards human-based methods, which weighs on academic rodent volumes. NIH stopped issuing funding notices that support animal models alone in July 2025. The FDA reported in April 2026 that it had met the first-year goals of its roadmap to reduce animal testing in preclinical safety work.
  • In East Asia, Chinese engineered mouse suppliers are expanding at home and abroad. GemPharmatech grew 2025 revenue by 15.5% to CNY 793.4 million and earned 19.1% of that revenue outside China. As a result, Western suppliers of engineered lines now face a growing Chinese competitor in export markets.

Animal Model Market Size and Forecast

Table 1: Animal Model Market Size and Forecast

Market size and forecast Value
Market size in 2025 USD 2.0 billion
Estimated market size in 2026 USD 2.1 billion
Projected market size by 2036 USD 3.8 billion
CAGR from 2026 to 2036 6.1%

Source: Future Market Insights analysis of the animal model market, 2026.

Analyst Perspective

“Research buyers select a model for the scientific question first, then compare health status, delivery time and price per study cohort. Supplier differentiation rests on pairing engineered strains with in vivo study services, since sponsors prefer a single partner from breeding to final readout. Regulatory acceptance is the main barrier to substitution, because sponsors drop an animal study only after a regulator accepts the replacement method for that specific use.”

- Anurag Sharma, Principal Consultant, FMI

How is the Animal Model Market segmented?

  • By species: Rats, Mice, Guinea Pigs, Monkeys, Dogs, Pigs, Cats, and Other Species.
  • By end user: Academic & Research Institutions, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), and Other End Users.
  • By application: Basic and Applied Research, and Drug Discovery/Development.
  • By region: North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa.

Why do Mice lead by Species in the Animal Model Market in 2026?

Animal Model Market Analysis by Species
Animal Model Market Analysis by Species

Mice hold 65.0% of the Animal Model Market by species in 2026.

Mice lead because genetic tools and breeding speed make them the default starting point for a new disease target. Most engineered and humanized strains are built in mice, and official counts confirm the weight of the species. Mice made up 72.4% of animal uses in France in 2024. In Germany, mice accounted for 72.0% of the 1.33 million animals used in experiments that year. Great Britain reported that 85.0% of procedures to create and breed genetically altered animals in 2025 involved mice.

Revenue per mouse rises with genetic complexity, because a humanized line requires design, colony upkeep and genotyping that a standard outbred mouse does not. Japanese breeders sold 44,157 genetically modified mice in fiscal 2024, a 5.7% rise during a period of falling total mouse sales. Suppliers therefore earn more from fewer animals as research demand shifts to engineered strains.

Rats, Guinea Pigs, Monkeys, Dogs, Pigs, Cats and Other Species together hold the remaining 35.0% by species. Rats serve regulated safety work, with 64.0% of British experimental procedures on rats used for regulatory testing in 2025. Primates are few in number but high in value, and prices can offset falling volumes. Inotiv's research models revenue fell in the quarter to December 2025 on lower primate volumes, partly offset by higher selling prices.

Table 2: Species, 2026 Share

Leading Share 2026 market share
Mice 65.0%
All Other Segments Combined Share 35.0%

Why does Drug Discovery/Development lead by Application in the Animal Model Market in 2026?

Drug Discovery/Development accounts for 55.0% of the Animal Model Market by application in 2026.

Development work generates more revenue per animal than discovery science. Regulated studies use defined strains, larger species and controlled protocols, which raises the price of each study cohort. The volume of this work is substantial. In the European Union, more than 15 million animals were used for regulatory testing between 2015 and 2023. Much of that regulated work is placed with outside laboratories, which links this segment to the toxicity testing outsourcing market.

Basic and Applied Research holds the remaining 45.0% by application. By animal count, basic science is larger. It accounted for 54.0% of British experimental procedures in 2025 and 57.0% of animals used in Germany in 2024. Basic research relies more on low-priced mice, so its share of revenue is smaller than its share of animals.

Table 3: Application, 2026 Share

Leading Share 2026 market share
Drug Discovery/Development 55.0%
All Other Segments Combined Share 45.0%

Why do Academic & Research Institutions lead by End User in the Animal Model Market in 2026?

In FMI's 2026 assessment, Academic & Research Institutions hold 38.8% of Animal Model Market revenue by end user.

Universities and public institutes lead because they run the largest breeding programmes and buy the widest range of strains. In Great Britain, the ten organisations with the most procedures in 2025 were universities and public research bodies such as the Francis Crick Institute and the Medical Research Council. Together they carried out 53.0% of all procedures, and 80.7% of their procedures used mice. Nonprofit suppliers are adapting to this buyer base, and The Jackson Laboratory now pairs mouse genetics with stem cell and computational models after acquiring the New York Stem Cell Foundation.

Grant funding makes this buyer group sensitive to public budgets and funding rules. NIH will no longer issue funding calls that are limited to animal models. A single change in funding policy can therefore move academic orders for a full year.

Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs) and Other End Users together hold the remaining 61.2%. Industrial buyers order larger volumes per account and increasingly source models through outsourced studies tracked in the preclinical CRO market.

Table 4: End User, 2026 Share

Leading Share 2026 market share
Academic & Research Institutions 38.8%
All Other Segments Combined Share 61.2%

Source: Future Market Insights analysis of the animal model market, 2026.

What are the key drivers restraints and opportunities?

Animal model revenue depends on research budgets, the pace of drug development and the rules that decide when an animal study is needed. These three forces move on different timetables.

Driver

Drug development pipelines are refilling, which feeds model orders with a lag. Contract research bookings show the recovery. Among large providers, Charles River's safety assessment book-to-bill stayed above 1.0x for a third straight quarter through June 2026. Inotiv reported 1.16x for its discovery and safety business in its first fiscal 2026 quarter. Each booked study pulls through rodent and large-model orders over the following quarters, which supports supplier revenue into 2027.

Restraint

Public funders are paying to replace animal methods. NIH committed more than USD 150.0 million in March 2026 to its Complement-ARIE program for human-based methods. In June 2026 it opened an office to validate and scale animal-free models across the agency. The UK plans to end regulatory skin and eye irritation tests on animals by the end of 2026. Funding for these methods links to the new approach methodologies drug development market. Standard volume tests therefore face the earliest losses.

Opportunity

Suppliers can sell humanized models together with the studies that use them. Sponsors developing bispecific antibodies and cell therapies need engrafted mice and the pharmacology work to interpret them. Taconic acquired TransCure bioServices in January 2026 to offer humanized models, cohort generation and in vivo studies as one service. Bundled offers of this kind raise revenue per sponsor and reduce exposure to single-study substitution.

How do regulators and research funders shape animal model purchasing?

Regulators now publish target dates for removing specific tests. The FDA's April 2026 progress report lists draft guidance on reducing primate testing for monoclonal antibodies and a searchable database of accepted alternatives. The agency states that more than 90.0% of drugs that clear animal studies do not gain approval. Its March 2026 draft guidance requires sponsors to show reliability and human relevance before a new method replaces an animal study. Approval timing therefore depends on validation, which slows the pace of substitution.

Europe is following a similar path for chemicals. The European Commission adopted a roadmap on 1 June 2026 for phasing out animal testing in chemical safety assessments. It plans legislative proposals for short-term actions by the end of 2029. The UK expects to reduce pharmacokinetic studies in dogs and primates by 2030. Regulatory toxicology demand is therefore more exposed than demand for disease models in basic science.

What limits reliable animal model supply and quality?

Primate supply depends on a few origin countries, which concentrates sourcing risk. Of the cynomolgus monkeys used for the first time in British experiments in 2025, 95.0% were born in Africa or Asia. In France, 81.0% of primates used for the first time in 2024 were born in Mauritius. Japan's suppliers sold only 422 monkeys in fiscal 2024 against 1,843 in the 2022 survey. The association cited the 2020 halt in monkey imports from China and higher prices. As a result, sponsors of primate studies face both price and availability risk.

Health and genetic status set the quality standard for rodents. Japanese suppliers sold almost all mice and rats as specific pathogen free animals. Colony health and genetic monitoring are therefore baseline procurement requirements, which raises the fixed cost of running a qualified breeding facility.

Where can model suppliers win additional business?

Suppliers can add business by combining strain portfolios with study services, local distribution and qualified non-animal methods. The FDA now maintains a searchable database of accepted alternatives, which defines where qualified methods can be offered alongside animal models. Local distribution shortens delivery times for engineered lines, which matters most for time-sensitive oncology and immunology studies. Each added capability lets a supplier retain a sponsor when the sponsor's method mix changes.

Animal Model Market by Country (2026 to 2036)

Table 5: Animal Model Market Country Growth Forecast

Animal Model Market Growth by Market map showing country CAGRs for 2026 to 2036: United States 7.5%, Japan 6.5%, Germany 6.4%, France 6.3%, United Kingdom 5.9%
Animal Model Market Growth by Market
Country CAGR, 2026 to 2036
United States 7.5%
Japan 6.5%
Germany 6.4%
France 6.3%
United Kingdom 5.9%

United States

Federal agencies in the United States are shifting research funding towards human-based methods while drug sponsors continue to order regulated animal studies. NIH stopped issuing funding notices that support animal models alone in July 2025. In June 2026 it created ORIVA, an office to develop and validate animal-free methods across its institutes. The FDA reported first-year progress on its own testing roadmap in April 2026.

The effect differs by buyer. Academic demand for standard rodents is exposed to federal funding rules, while drug developers are increasing demand for humanized lines. Taconic will distribute genOway's target-specific humanized mice to US researchers under an October 2026 agreement. Sponsors developing T-cell engagers, antibody-drug conjugates and CAR-T therapies are the target users of these lines. The French developer expects the agreement to double its US business.

Higher-value engineered strains explain how the United States can still deliver a 7.5% CAGR from 2026 to 2036 while animal counts face pressure. Monoclonal antibody programmes are the most exposed area, because the FDA plans to reduce primate testing for them. Those studies command the highest prices, so their loss would weigh on revenue more than on volumes. Suppliers with humanized mice and in-house study capacity hold the stronger position, while breeders of standard stock face the larger share of the decline.

Japan

Japan's breeders sell fewer animals each survey, but research buyers are paying for more specialized strains. Japan's national laboratory animal association surveyed 29 suppliers and found that 2.46 million mice were sold in the year to March 2025. That was 4.9% below the 2022 survey and only about a quarter of the 1988 peak. Rat sales fell 14.5%, while genetically modified mouse sales rose 5.7% to 44,157 animals over the same period.

Foreign specialists are entering to serve that engineered demand. JETRO describes Japan as the third-largest preclinical research market after the United States and China. GemPharmatech entered the Shonan Health Innovation Park in 2025 to serve Japanese buyers on site. It has also formed strategic partnerships with FUJIFILM Wako Pure Chemical and a Japanese immunology research institute. Local partners give foreign model owners a faster route to Japanese customers.

Primate access is the weak point in Japan. Surveyed suppliers sold only 422 monkeys in the latest survey year, while 5,376 monkeys were imported in 2024. The association attributes much of that difference to direct imports by users and purchases outside its survey. Primate study sponsors therefore manage supply themselves or through contract laboratories. Rodent quality is less of a constraint, since surveyed suppliers deliver almost all mice and rats with specific pathogen free status. Engineered lines and on-site partnerships lift Japanese model revenue at 6.5% a year between 2026 and 2036, the second-highest rate among the profiled countries. Suppliers that breed licensed lines inside Japan can shorten delivery times for these buyers.

Germany

Germany has recorded five straight years of lower animal use, and part of the cause is commercial. The Federal Institute for Risk Assessment reported 1.33 million vertebrates and cephalopods used in experiments in 2024, a fall of 9.0%. Together with animals bred but not used, the total fell 8.2% to 1.95 million. Basic research accounted for 57.0% of animals used, translational research 15.0% and regulatory purposes 17.0%.

A September 2026 review by the institute found that the decline is likely to have several causes. Federal funding for life sciences grew more slowly than for other fields. About 30.0% of German companies doing pharmaceutical and medical device research already conduct some of it abroad. Industry groups cite bureaucratic approval procedures for animal studies as a barrier. In vitro methods gained ground in neuroscience and immunology, but not in oncology.

Model demand still has room to grow in value. Patent and trademark filings for pharmaceutical products rose 12.0% in 2024, which indicates that discovery activity is holding up even as animal counts fall. That combination of steady discovery and fewer animals sits behind a 6.4% CAGR for Germany during 2026 to 2036. Work moved abroad can still generate orders for foreign contract laboratories and their model suppliers. Oncology programmes continue to rely on mouse models, so engineered tumour and immune strains face less pressure than regulatory stock. Slow approval of animal study protocols remains a drag, because it delays orders. Suppliers that hold German facility licences and offer local cohort supply can shorten those delays for academic buyers.

France

France has built a cluster of humanized mouse specialists that sell to drug developers worldwide. genOway, based in Lyon, works with 17 large pharmaceutical groups, more than 170 biotech companies and more than 380 academic institutions. A study published in February 2026 described its humanized Fc receptor mouse as a tool to rank antibody candidates. Export demand for such lines links French suppliers to global drug development budgets more than to domestic research spending.

Official data show engineered animals at the centre of French demand. France recorded 2,041,157 animal uses in 2024, close to the 2023 total. Uses in experimental procedures fell 8.3% to 1,381,683. Reported colony maintenance and line creation rose, which the ministry attributes to more precise reporting. The ministry also halved the use of mice for routine antibody production by the ascites method between 2022 and 2024. French revenue is expected to compound at 6.3% a year from 2026 to 2036 on the strength of these engineered lines.

Export sales of specialized strains account for much of that outlook, because domestic demand is steady but not rising in volume. Primate uses fell to 2,905 from 3,459 a year earlier. Export sales of engineered lines are more exposed to currency and shipping costs than to French research budgets. Suppliers that keep breeding partners in the United States and Asia can protect delivery times. French breeders therefore compete on scientific design more than on price per animal.

United Kingdom

The United Kingdom has published dated targets for replacing specific animal tests, and they set the pace for its model market. The government's November 2025 strategy aims to end regulatory skin and eye irritation tests on animals by the end of 2026. It targets an end to botulinum toxin potency tests on mice by 2027 and fewer pharmacokinetic studies in dogs and primates by 2030. In August 2026 the government added GBP 20.0 million for a preclinical translational models hub in Cambridge.

Procedures have already fallen to a record low. Great Britain recorded 2.54 million procedures in 2025, a decline of 3.8%. Breeding of genetically altered animals now accounts for 48.0% of all procedures. Demand is concentrated in a few buyers, since ten universities and public research bodies carried out 53.0% of all procedures in 2025.

Regulatory testing volumes are the first to decline, which affects suppliers of rats and dogs most. Academic breeding of engineered mice holds up better, because no full replacement exists for whole-organism disease studies. Mice remain the main species in basic research on the immune and nervous systems. Concentrated buying also gives the largest universities strong pricing power with outside suppliers. Suppliers that run colonies on university sites can retain this business as volumes fall. The new translational models hub may shift some early discovery work away from animals within a few years. These forces combine to give the United Kingdom the slowest outlook in this group, a 5.9% CAGR over 2026 to 2036.

Who are the notable companies in the Animal Model Market?

Charles River Laboratories, The Jackson Laboratory, Taconic Biosciences and genOway represent the main supplier models in research animals. Charles River is a broad supplier whose research models and services segment earned USD 846.1 million in 2025, or 21.1% of group revenue. It breeds more than 140 rodent stocks and strains in production sites across 7 countries. The company states that the FDA and foreign regulators require most new drug candidates to be tested on research models before human trials. In January 2026 it paid USD 510.0 million for K.F. (Cambodia) assets, a supplier that had provided slightly above 30.0% of the primates it sourced for safety studies over the previous two years. It reported lower North American small-model sales from academic and government accounts in the second quarter of 2026, against strong orders in China from mid-tier biotech and CRO clients. It also expects to close or consolidate about 12 more sites over two years.

Animal Model Market Company Highlight
Animal Model Market Company Highlight

The Jackson Laboratory operates as a nonprofit with nearly 3,000 employees and campuses in the United States and Japan. It describes mouse genetics and preclinical modelling as its core strength and now adds cell and computational models through its NYSCF unit. Taconic and genOway focus on humanized and target-specific mice for drug developers. Taconic launched its hG-CSF KI NOG mouse in June 2026 for research on human neutrophils. genOway reported EUR 21.0 million of revenue in 2025 and targets EUR 5.0 million to EUR 10.0 million of Japanese revenue through its new Tokyo subsidiary.

Other suppliers compete on primates, regional reach or study services. Inotiv earned USD 325.1 million from research models and services in its 2025 fiscal year. Its research models revenue fell 5.4% in the quarter to December 2025 on lower primate volumes, and a US bankruptcy court confirmed its plan of reorganization on 14 July 2026. GemPharmatech served nearly 2,900 customers in China and nearly 400 abroad in 2025. Industrial clients produced more than 75.0% of its 2025 overseas revenue, and it opened a US regional base in 2025. Crown Bioscience, part of JSR Life Sciences, sells oncology studies built on patient-derived models and organoids. Competitive advantage across these firms rests on strain rights, colony health records and study capacity.

Key Developments in the Animal Model Market

  • On 14 January 2026, Charles River Laboratories completed the USD 510.0 million acquisition of certain assets of K.F. (Cambodia) Ltd, a supplier of non-human primates. USD 335.0 million was paid at closing and USD 175.0 million is deferred until post-close conditions are met.
  • On 20 January 2026, Taconic Biosciences acquired TransCure bioServices SAS of Archamps, France, a provider of preclinical studies using humanized immune system mice.
  • In February 2026, genOway established its subsidiary genOway Japan K.K. in Tokyo to sell its preclinical models directly to Japanese customers.

Key Players in the Animal Model Market

  • Charles River Laboratories International, Inc.
  • The Jackson Laboratory
  • Taconic Biosciences, Inc.
  • genOway S.A.
  • Crown Bioscience (JSR Life Sciences)
  • Inotiv, Inc.
  • GemPharmatech Co., Ltd.

Animal Model Market Report Scope

Table 6: Animal Model Market Report Scope

Coverage field Report scope
Market definition Revenue from the sale of purpose-bred research animals and directly related model services, including colony management, cohort generation and custom model creation. Contract study fees that are not tied to model supply are excluded.
Species Rats; Mice; Guinea Pigs; Monkeys; Dogs; Pigs; Cats; Other Species
End User Academic & Research Institutions; Pharmaceutical Companies; Biotechnology Companies; Contract Research Organizations (CROs); Other End Users
Application Basic and Applied Research; Drug Discovery/Development
Model types reviewed Outbred, inbred, genetically engineered and humanized immune system strains
Regions covered North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, Middle East and Africa
Profiled markets United States, Japan, Germany, France, United Kingdom
Companies covered Charles River Laboratories International, Inc.; The Jackson Laboratory; Taconic Biosciences, Inc.; genOway S.A.; Crown Bioscience (JSR Life Sciences); Inotiv, Inc.; GemPharmatech Co., Ltd.
Quantitative Units USD billion

Source: Future Market Insights analysis of the animal model market, 2026.

Animal Model Market Research Methodology

The animal model assessment draws on national animal use statistics, regulatory publications and supplier disclosures. FMI measures annual revenue from research animals and related model services sold to research and drug development buyers. Segment values are classified by species, application and end user. Country forecasts reflect local research funding, regulatory change and supplier activity over the same 2026 to 2036 period. Animal counts, supplier revenue and policy milestones are reviewed as separate measures.

Animal Model Market by Segments

Animal Model Market segmented by Species:

  • Rats
  • Mice
  • Guinea Pigs
  • Monkeys
  • Dogs
  • Pigs
  • Cats
  • Other Species

Animal Model Market segmented by End User:

  • Academic & Research Institutions
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Other End Users

Animal Model Market segmented by Application:

  • Basic and Applied Research
  • Drug Discovery/Development

Animal Model Market by Region

  • North America
    • United States
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Chile
  • Western Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Benelux
    • Nordics
  • Eastern Europe
    • Poland
    • Czech Republic
    • Romania
    • Hungary
  • East Asia
    • China
    • Japan
    • South Korea
  • South Asia and Pacific
    • India
    • ASEAN
    • Australia and New Zealand
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Türkiye
    • Israel

Research Sources and Bibliography

  • [1] Ministère de l'Enseignement supérieur et de la Recherche, Direction générale de la recherche et de l'innovation. (2026, February 20). Utilisation d'animaux à des fins scientifiques dans les établissements français: Enquête statistique 2024.
  • [2] Japan Laboratory Animal Association (Nichidokyo). (2025, December 17). Annual survey of laboratory animal sales, April 2024 to March 2025. https://www.nichidokyo.or.jp/pdf/production/R6-souhanbaisu.pdf
  • [3] U.S. Food and Drug Administration. (2026, April 20). FDA Achieves Year 1 Goals in Reducing Animal Testing in Drug Development.
  • [4] Home Office. (2026, July 9; updated 2026, August 27). Annual statistics of scientific procedures on living animals, Great Britain 2025.
  • [5] Charles River Laboratories International, Inc. (2026, February 18). Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance. https://ir.criver.com/news-releases/news-release-details/charles-river-laboratories-announces-fourth-quarter-and-full-14/
  • [6] Charles River Laboratories International, Inc. (2026, August 5). Charles River Laboratories 2Q 2026 Results presentation. https://ir.criver.com/static-files/25889b2c-1cda-4d0f-aca6-b8261fce9ee8
  • [7] U.S. Food and Drug Administration. (2026, March 18). FDA Releases Draft Guidance on Alternatives to Animal Testing in Drug Development. https://www.fda.gov/news-events/press-announcements/fda-releases-draft-guidance-alternatives-animal-testing-drug-development
  • [8] Taconic Biosciences, Inc. (2026, June 8). Taconic Biosciences Launches hG-CSF KI NOG Mouse for Human-Specific Neutrophil Research. https://www.taconic.com/resources/taconic-launches-hg-csf-ki-nog-mouse-for-human-neutrophil-research
  • [9] Charles River Laboratories International, Inc. (2026). Form 10-K for the fiscal year ended December 27, 2025. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1100682/000110068226000022/crl-20251227.htm
  • [10] Charles River Laboratories International, Inc. (2026, January 12). Charles River Laboratories Provides Business Updates. https://ir.criver.com/news-releases/news-release-details/charles-river-laboratories-provides-business-updates/
  • [11] National Institutes of Health, Office of Extramural Research. (2025, July 10). NIH Funding Announcements to Align with NIH Initiative to Prioritize Human-based Research. https://grants.nih.gov/news-events/nih-extramural-nexus-news/2025/07/nih-funding-announcements-to-align-with-nih-initiative-to-prioritize-human-based-research
  • [12] GemPharmatech Co., Ltd. (2026, April 23). 2025 Annual Report. Shanghai Stock Exchange disclosure via CNINFO. https://static.cninfo.com.cn/finalpage/2026-04-23/1225148253.PDF
  • [13] Bundesinstitut für Risikobewertung (BfR). (2025, December 9). Erstmals weniger als zwei Millionen Versuchstiere. Press release No. 31/2025.
  • [14] Inotiv, Inc. (2026, February 9). Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update. https://www.inotiv.com/news/inotiv-reports-first-quarter-financial-results-for-fiscal-2026-and-provides-business-update
  • [15] European Commission. (2026, June 1). Communication from the Commission: Roadmap towards phasing out animal testing for chemical safety assessments, C(2026) 3497 final. https://single-market-economy.ec.europa.eu/document/download/dff698bf-4852-4898-9f0d-7878382fbff6_en?filename=C_2026_3497_F1_COMMUNICATION_FROM_COMMISSION_EN_V4_P1_4771149.PDF
  • [16] Understanding Animal Research. (2026, July 9). Ten organisations carried out half of all animal research in Great Britain in 2025. https://www.understandinganimalresearch.org.uk/news/ten-organisations-carried-out-half-of-all-animal-research-in-great-britain-in-2025
  • [17] The Jackson Laboratory. (2026). JAX-NYSCF, accessed 4 November 2026. https://www.jax.org/nyscf
  • [18] National Institutes of Health. (2026, March 18). NIH invests $150 million in human-based research to reduce use of animal models. https://www.nih.gov/news-events/news-releases/nih-invests-150-million-human-based-research-reduce-use-animal-models
  • [19] National Institutes of Health. (2026, June 15). NIH launches new office to advance human-based research and reduce animal use. https://www.nih.gov/news-events/news-releases/nih-launches-new-office-advance-human-based-research-reduce-animal-use
  • [20] Department for Science, Innovation and Technology. (2025, November 11). Animal testing to be phased out faster as UK unveils roadmap for alternative methods. https://www.gov.uk/government/news/animal-testing-to-be-phased-out-faster-as-uk-unveils-roadmap-for-alternative-methods
  • [21] Taconic Biosciences, Inc. (2026, January 20). Taconic Biosciences Acquires TransCure bioServices, Building a Comprehensive Global Platform for Humanized Mouse Translational Research. https://www.taconic.com/resources/taconic-biosciences-transcure-bioservices-acquisition
  • [22] genOway S.A. (2026). Investor relations: press releases of 25 March, 30 March and 23 September 2026, accessed 4 November 2026. https://www.genoway.com/investors
  • [23] Taconic Biosciences, Inc. (2026, October 1). Taconic Biosciences and genOway Partner to Expand U.S. Access to Advanced Humanized Mouse Models. https://www.taconic.com/resources/taconic-genoway-humanized-mouse-model-partnership
  • [24] Crown Bioscience. (2026, July 16). Crown Bioscience Joins C-Path's NAMs Developer Coalition to Advance Human-Relevant Models in Drug Development. https://www.crownbio.com/about-us/news-and-events/crown-bioscience-joins-c-paths-nams-developer-coalition-to-advance-human-relevant-models-in-drug-development
  • [25] Inotiv, Inc. (2026, July 14). Inotiv Announces Confirmation of Plan of Reorganization. https://www.inotiv.com/news/inotiv-announces-confirmation-of-plan-of-reorganization
  • [26] Japan External Trade Organization (JETRO). (2026, May 18). genOway, a Provider of Highly Predictive Preclinical Research Models and Solutions, Establishes its Japanese subsidiary in Chuo-ku, Tokyo. https://www.jetro.go.jp/en/invest/newsroom/2026/253485e587647f7e.html
  • [27] Bundesinstitut für Risikobewertung (BfR). (2026, September 2). Sinkende Versuchstierzahlen in Deutschland: Mögliche Gründe für die Reduktion und Auswirkung auf den Forschungsstandort. https://www.bfr.bund.de/assets/01_Ver%C3%B6ffentlichungen/Wissenschaftsberichte_deutsch/sinkende-versuchstierzahlen-in-deutschland.pdf
  • [28] genOway S.A. (2026, February 23). Revolutionizing the Prediction of Antibody Therapies in Humans with a Unique Mouse Model. https://www.genoway.com/news-events/pr-fcgr-2026
  • [29] Department for Science, Innovation and Technology. (2026, August 12). Patients to benefit from faster access to medicines as UK moves away from animal testing in science. https://www.gov.uk/government/news/patients-to-benefit-from-faster-access-to-medicines-as-uk-moves-away-from-animal-testing-in-science
  • [30] Inotiv, Inc. (2025, December 3). Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update. https://www.inotiv.com/news/inotiv-reports-fourth-quarter-and-full-year-financial-results-for-fiscal-2025-and-provides-business-update
  • [31] The Jackson Laboratory. (2026, July 21). Broad Institute, Boston Children's Hospital, and The Jackson Laboratory launch the Center for Therapeutic Genetics. https://www.jax.org/news-and-insights/2026/july/jax-launches-the-center-for-therapeutic-genetics
  • [32] Crown Bioscience. (2026, April 21). Crown Bioscience and Turbine Partner to Connect AI-Driven Prediction with Organoid Validation in Translational Oncology. https://www.crownbio.com/about-us/news-and-events/crown-bioscience-and-turbine-partner-to-connect-ai-driven-prediction-with-organoid-validation-in-translational-oncology

Table of Content

  1. Key Takeaways
    • Market Size and CAGR
    • Top Growth Driver
    • Fastest Growing Segment
    • Leading Region
    • Key Companies
    • Emerging Opportunities
  2. Executive Summary
    • Global Market Outlook
    • Demand-side Trends
    • Supply-side Trends
    • Technology Roadmap Analysis
    • Analysis and Recommendations
    • Analyst Perspective (What is happening? Why now? What should investors know?)
    • Key Questions Answered
      • How large is the market?
      • What is the CAGR?
      • What are key trends?
      • Which region dominates?
      • Who are the leaders?
Read More...
  1. Market Overview
    • Market Coverage / Taxonomy
    • Market Definition / Scope / Limitations
  2. Research Methodology
    • Chapter Orientation
    • Analytical Lens and Working Hypotheses
      • Market Structure, Signals, and Trend Drivers
      • Benchmarking and Cross-market Comparability
      • Market Sizing, Forecasting, and Opportunity Mapping
    • Research Design and Evidence Framework
      • Desk Research Programme (Secondary Evidence)
      • Expert Input and Fieldwork (Primary Evidence)
      • Tooling, Models, and Reference Databases
    • Data Engineering and Model Build
    • Quality Assurance and Audit Trail
  3. Market Background
    • Market Dynamics (Drivers, Restraints, Opportunity, Trends)
    • Scenario Forecast (Optimistic, Likely, Conservative)
    • Impact Analysis
      • AI Impact
      • Sustainability Impact
      • Regulatory Impact
      • Technology Impact
    • Consumer / Buyer Analysis
      • Purchase Drivers
      • Adoption Barriers
      • Buyer Journey
    • Opportunity Map Analysis
    • Product Life Cycle Analysis
    • Supply Chain Analysis
    • Investment Feasibility Matrix
    • Value Chain Analysis
    • PESTLE and Porter's Analysis
    • Regulatory Landscape
    • Regional Parent Market Outlook
    • Production and Consumption Statistics
    • Import and Export Statistics
  4. Global Market Analysis and Forecast, 2021 to 2036
    • Historical Market Size Value (USD Billion) Analysis, 2021 to 2025
    • Current and Future Market Size Value (USD Billion) Projections, 2026 to 2036
      • Y-o-Y Growth Trend Analysis
      • Absolute $ Opportunity Analysis
  5. Global Market Pricing Analysis, 2021 to 2036
  6. Global Market Analysis and Forecast, By Species, 2021 to 2036
    • Introduction / Key Findings
    • Historical Market Size Value (USD Billion) Analysis By Species, 2021 to 2025
    • Current and Future Market Size Value (USD Billion) Analysis and Forecast By Species, 2026 to 2036
      • Rats
      • Mice
      • Guinea Pigs
      • Monkeys
      • Dogs
      • Pigs
      • Cats
      • Other Species
    • Y-o-Y Growth Trend Analysis By Species, 2021 to 2025
    • Absolute $ Opportunity Analysis By Species, 2026 to 2036
  7. Global Market Analysis and Forecast, By End User, 2021 to 2036
    • Introduction / Key Findings
    • Historical Market Size Value (USD Billion) Analysis By End User, 2021 to 2025
    • Current and Future Market Size Value (USD Billion) Analysis and Forecast By End User, 2026 to 2036
      • Academic & Research Institutions
      • Pharmaceutical Companies
      • Biotechnology Companies
      • Contract Research Organizations (CROs)
      • Other End Users
    • Y-o-Y Growth Trend Analysis By End User, 2021 to 2025
    • Absolute $ Opportunity Analysis By End User, 2026 to 2036
  8. Global Market Analysis and Forecast, By Application, 2021 to 2036
    • Introduction / Key Findings
    • Historical Market Size Value (USD Billion) Analysis By Application, 2021 to 2025
    • Current and Future Market Size Value (USD Billion) Analysis and Forecast By Application, 2026 to 2036
      • Basic and Applied Research
      • Drug Discovery/Development
    • Y-o-Y Growth Trend Analysis By Application, 2021 to 2025
    • Absolute $ Opportunity Analysis By Application, 2026 to 2036
  9. Global Market Analysis and Forecast, By Region, 2021 to 2036
    • Introduction
    • Historical Market Size Value (USD Billion) Analysis By Region, 2021 to 2025
    • Current Market Size Value (USD Billion) Analysis and Forecast By Region, 2026 to 2036
      • North America
      • Latin America
      • Western Europe
      • Eastern Europe
      • East Asia
      • South Asia and Pacific
      • Middle East and Africa
    • Market Attractiveness Analysis By Region
  10. North America Market Analysis and Forecast, By Country, 2021 to 2036
    • Historical Market Size Value (USD Billion) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Billion) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • United States
        • Canada
      • By Species
      • By End User
      • By Application
    • Market Attractiveness Analysis
      • By Country
      • By Species
      • By End User
      • By Application
    • Key Takeaways
  11. Latin America Market Analysis and Forecast, By Country
    • Historical Market Size Value (USD Billion) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Billion) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Chile
      • By Species
      • By End User
      • By Application
    • Market Attractiveness Analysis
      • By Country
      • By Species
      • By End User
      • By Application
    • Key Takeaways
  12. Western Europe Market Analysis and Forecast, By Country
    • Historical Market Size Value (USD Billion) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Billion) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • Germany
        • France
        • United Kingdom
        • Italy
        • Spain
        • Benelux
        • Nordics
      • By Species
      • By End User
      • By Application
    • Market Attractiveness Analysis
      • By Country
      • By Species
      • By End User
      • By Application
    • Key Takeaways
  13. Eastern Europe Market Analysis and Forecast, By Country
    • Historical Market Size Value (USD Billion) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Billion) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • Poland
        • Czech Republic
        • Romania
        • Hungary
      • By Species
      • By End User
      • By Application
    • Market Attractiveness Analysis
      • By Country
      • By Species
      • By End User
      • By Application
    • Key Takeaways
  14. East Asia Market Analysis and Forecast, By Country
    • Historical Market Size Value (USD Billion) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Billion) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • China
        • Japan
        • South Korea
      • By Species
      • By End User
      • By Application
    • Market Attractiveness Analysis
      • By Country
      • By Species
      • By End User
      • By Application
    • Key Takeaways
  15. South Asia and Pacific Market Analysis and Forecast, By Country
    • Historical Market Size Value (USD Billion) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Billion) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • India
        • ASEAN
        • Australia and New Zealand
      • By Species
      • By End User
      • By Application
    • Market Attractiveness Analysis
      • By Country
      • By Species
      • By End User
      • By Application
    • Key Takeaways
  16. Middle East and Africa Market Analysis and Forecast, By Country
    • Historical Market Size Value (USD Billion) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Billion) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • GCC Countries
        • South Africa
        • Türkiye
        • Israel
      • By Species
      • By End User
      • By Application
    • Market Attractiveness Analysis
      • By Country
      • By Species
      • By End User
      • By Application
    • Key Takeaways
  17. Key Countries Market Analysis
    • United States
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
    • Canada
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
    • Mexico
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
    • Brazil
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
    • Chile
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
    • Germany
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
    • United Kingdom
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
    • Italy
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
    • Spain
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
    • France
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
    • India
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
    • ASEAN
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
    • Australia and New Zealand
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
    • China
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
    • Japan
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
    • South Korea
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
    • Poland
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
    • Hungary
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
    • Türkiye
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
    • South Africa
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Species
        • By End User
        • By Application
  18. Market Structure Analysis
    • Competition Dashboard
    • Competition Benchmarking
    • Market Share Analysis of Top Players
      • By Regional
      • By Species
      • By End User
      • By Application
      • Emerging Startups
      • Innovation Benchmarking
    • Competition Analysis
      • Competition Deep Dive
        • Charles River Laboratories International, Inc.
          • Overview
          • Product Portfolio
          • Profitability by Market Segments
          • Sales Footprint
          • Strategy Overview
            • Marketing Strategy
            • Product Strategy
            • Channel Strategy
        • Inotiv, Inc.
        • Taconic Biosciences, Inc.
        • genOway S.A.
        • GemPharmatech Co., Ltd.
        • The Jackson Laboratory
        • Crown Bioscience (JSR Life Sciences)
      • Case Studies
      • Success Stories
      • Recent Developments
  19. Assumptions & Acronyms Used

List of Tables

  • Table 1: Global Market Value (USD Billion) Forecast by Region, 2021 to 2036
  • Table 2: Global Market Value (USD Billion) Forecast by Species, 2021 to 2036
  • Table 3: Global Market Value (USD Billion) Forecast by End User, 2021 to 2036
  • Table 4: Global Market Value (USD Billion) Forecast by Application, 2021 to 2036
  • Table 5: North America Market Value (USD Billion) Forecast by Country, 2021 to 2036
  • Table 6: North America Market Value (USD Billion) Forecast by Species, 2021 to 2036
  • Table 7: North America Market Value (USD Billion) Forecast by End User, 2021 to 2036
  • Table 8: North America Market Value (USD Billion) Forecast by Application, 2021 to 2036
  • Table 9: Latin America Market Value (USD Billion) Forecast by Country, 2021 to 2036
  • Table 10: Latin America Market Value (USD Billion) Forecast by Species, 2021 to 2036
  • Table 11: Latin America Market Value (USD Billion) Forecast by End User, 2021 to 2036
  • Table 12: Latin America Market Value (USD Billion) Forecast by Application, 2021 to 2036
  • Table 13: Western Europe Market Value (USD Billion) Forecast by Country, 2021 to 2036
  • Table 14: Western Europe Market Value (USD Billion) Forecast by Species, 2021 to 2036
  • Table 15: Western Europe Market Value (USD Billion) Forecast by End User, 2021 to 2036
  • Table 16: Western Europe Market Value (USD Billion) Forecast by Application, 2021 to 2036
  • Table 17: Eastern Europe Market Value (USD Billion) Forecast by Country, 2021 to 2036
  • Table 18: Eastern Europe Market Value (USD Billion) Forecast by Species, 2021 to 2036
  • Table 19: Eastern Europe Market Value (USD Billion) Forecast by End User, 2021 to 2036
  • Table 20: Eastern Europe Market Value (USD Billion) Forecast by Application, 2021 to 2036
  • Table 21: East Asia Market Value (USD Billion) Forecast by Country, 2021 to 2036
  • Table 22: East Asia Market Value (USD Billion) Forecast by Species, 2021 to 2036
  • Table 23: East Asia Market Value (USD Billion) Forecast by End User, 2021 to 2036
  • Table 24: East Asia Market Value (USD Billion) Forecast by Application, 2021 to 2036
  • Table 25: South Asia and Pacific Market Value (USD Billion) Forecast by Country, 2021 to 2036
  • Table 26: South Asia and Pacific Market Value (USD Billion) Forecast by Species, 2021 to 2036
  • Table 27: South Asia and Pacific Market Value (USD Billion) Forecast by End User, 2021 to 2036
  • Table 28: South Asia and Pacific Market Value (USD Billion) Forecast by Application, 2021 to 2036
  • Table 29: Middle East and Africa Market Value (USD Billion) Forecast by Country, 2021 to 2036
  • Table 30: Middle East and Africa Market Value (USD Billion) Forecast by Species, 2021 to 2036
  • Table 31: Middle East and Africa Market Value (USD Billion) Forecast by End User, 2021 to 2036
  • Table 32: Middle East and Africa Market Value (USD Billion) Forecast by Application, 2021 to 2036

List of Figures

  • Figure 1: Global Market Pricing Analysis
  • Figure 2: Global Market Value (USD Billion) Forecast 2021-2036
  • Figure 3: Global Market Value Share and BPS Analysis by Species, 2026 and 2036
  • Figure 4: Global Market Y-o-Y Growth Comparison by Species, 2026-2036
  • Figure 5: Global Market Attractiveness Analysis by Species
  • Figure 6: Global Market Value Share and BPS Analysis by End User, 2026 and 2036
  • Figure 7: Global Market Y-o-Y Growth Comparison by End User, 2026-2036
  • Figure 8: Global Market Attractiveness Analysis by End User
  • Figure 9: Global Market Value Share and BPS Analysis by Application, 2026 and 2036
  • Figure 10: Global Market Y-o-Y Growth Comparison by Application, 2026-2036
  • Figure 11: Global Market Attractiveness Analysis by Application
  • Figure 12: Global Market Value (USD Billion) Share and BPS Analysis by Region, 2026 and 2036
  • Figure 13: Global Market Y-o-Y Growth Comparison by Region, 2026-2036
  • Figure 14: Global Market Attractiveness Analysis by Region
  • Figure 15: North America Market Incremental Dollar Opportunity, 2026-2036
  • Figure 16: Latin America Market Incremental Dollar Opportunity, 2026-2036
  • Figure 17: Western Europe Market Incremental Dollar Opportunity, 2026-2036
  • Figure 18: Eastern Europe Market Incremental Dollar Opportunity, 2026-2036
  • Figure 19: East Asia Market Incremental Dollar Opportunity, 2026-2036
  • Figure 20: South Asia and Pacific Market Incremental Dollar Opportunity, 2026-2036
  • Figure 21: Middle East and Africa Market Incremental Dollar Opportunity, 2026-2036
  • Figure 22: North America Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 23: North America Market Value Share and BPS Analysis by Species, 2026 and 2036
  • Figure 24: North America Market Y-o-Y Growth Comparison by Species, 2026-2036
  • Figure 25: North America Market Attractiveness Analysis by Species
  • Figure 26: North America Market Value Share and BPS Analysis by End User, 2026 and 2036
  • Figure 27: North America Market Y-o-Y Growth Comparison by End User, 2026-2036
  • Figure 28: North America Market Attractiveness Analysis by End User
  • Figure 29: North America Market Value Share and BPS Analysis by Application, 2026 and 2036
  • Figure 30: North America Market Y-o-Y Growth Comparison by Application, 2026-2036
  • Figure 31: North America Market Attractiveness Analysis by Application
  • Figure 32: Latin America Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 33: Latin America Market Value Share and BPS Analysis by Species, 2026 and 2036
  • Figure 34: Latin America Market Y-o-Y Growth Comparison by Species, 2026-2036
  • Figure 35: Latin America Market Attractiveness Analysis by Species
  • Figure 36: Latin America Market Value Share and BPS Analysis by End User, 2026 and 2036
  • Figure 37: Latin America Market Y-o-Y Growth Comparison by End User, 2026-2036
  • Figure 38: Latin America Market Attractiveness Analysis by End User
  • Figure 39: Latin America Market Value Share and BPS Analysis by Application, 2026 and 2036
  • Figure 40: Latin America Market Y-o-Y Growth Comparison by Application, 2026-2036
  • Figure 41: Latin America Market Attractiveness Analysis by Application
  • Figure 42: Western Europe Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 43: Western Europe Market Value Share and BPS Analysis by Species, 2026 and 2036
  • Figure 44: Western Europe Market Y-o-Y Growth Comparison by Species, 2026-2036
  • Figure 45: Western Europe Market Attractiveness Analysis by Species
  • Figure 46: Western Europe Market Value Share and BPS Analysis by End User, 2026 and 2036
  • Figure 47: Western Europe Market Y-o-Y Growth Comparison by End User, 2026-2036
  • Figure 48: Western Europe Market Attractiveness Analysis by End User
  • Figure 49: Western Europe Market Value Share and BPS Analysis by Application, 2026 and 2036
  • Figure 50: Western Europe Market Y-o-Y Growth Comparison by Application, 2026-2036
  • Figure 51: Western Europe Market Attractiveness Analysis by Application
  • Figure 52: Eastern Europe Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 53: Eastern Europe Market Value Share and BPS Analysis by Species, 2026 and 2036
  • Figure 54: Eastern Europe Market Y-o-Y Growth Comparison by Species, 2026-2036
  • Figure 55: Eastern Europe Market Attractiveness Analysis by Species
  • Figure 56: Eastern Europe Market Value Share and BPS Analysis by End User, 2026 and 2036
  • Figure 57: Eastern Europe Market Y-o-Y Growth Comparison by End User, 2026-2036
  • Figure 58: Eastern Europe Market Attractiveness Analysis by End User
  • Figure 59: Eastern Europe Market Value Share and BPS Analysis by Application, 2026 and 2036
  • Figure 60: Eastern Europe Market Y-o-Y Growth Comparison by Application, 2026-2036
  • Figure 61: Eastern Europe Market Attractiveness Analysis by Application
  • Figure 62: East Asia Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 63: East Asia Market Value Share and BPS Analysis by Species, 2026 and 2036
  • Figure 64: East Asia Market Y-o-Y Growth Comparison by Species, 2026-2036
  • Figure 65: East Asia Market Attractiveness Analysis by Species
  • Figure 66: East Asia Market Value Share and BPS Analysis by End User, 2026 and 2036
  • Figure 67: East Asia Market Y-o-Y Growth Comparison by End User, 2026-2036
  • Figure 68: East Asia Market Attractiveness Analysis by End User
  • Figure 69: East Asia Market Value Share and BPS Analysis by Application, 2026 and 2036
  • Figure 70: East Asia Market Y-o-Y Growth Comparison by Application, 2026-2036
  • Figure 71: East Asia Market Attractiveness Analysis by Application
  • Figure 72: South Asia and Pacific Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 73: South Asia and Pacific Market Value Share and BPS Analysis by Species, 2026 and 2036
  • Figure 74: South Asia and Pacific Market Y-o-Y Growth Comparison by Species, 2026-2036
  • Figure 75: South Asia and Pacific Market Attractiveness Analysis by Species
  • Figure 76: South Asia and Pacific Market Value Share and BPS Analysis by End User, 2026 and 2036
  • Figure 77: South Asia and Pacific Market Y-o-Y Growth Comparison by End User, 2026-2036
  • Figure 78: South Asia and Pacific Market Attractiveness Analysis by End User
  • Figure 79: South Asia and Pacific Market Value Share and BPS Analysis by Application, 2026 and 2036
  • Figure 80: South Asia and Pacific Market Y-o-Y Growth Comparison by Application, 2026-2036
  • Figure 81: South Asia and Pacific Market Attractiveness Analysis by Application
  • Figure 82: Middle East and Africa Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 83: Middle East and Africa Market Value Share and BPS Analysis by Species, 2026 and 2036
  • Figure 84: Middle East and Africa Market Y-o-Y Growth Comparison by Species, 2026-2036
  • Figure 85: Middle East and Africa Market Attractiveness Analysis by Species
  • Figure 86: Middle East and Africa Market Value Share and BPS Analysis by End User, 2026 and 2036
  • Figure 87: Middle East and Africa Market Y-o-Y Growth Comparison by End User, 2026-2036
  • Figure 88: Middle East and Africa Market Attractiveness Analysis by End User
  • Figure 89: Middle East and Africa Market Value Share and BPS Analysis by Application, 2026 and 2036
  • Figure 90: Middle East and Africa Market Y-o-Y Growth Comparison by Application, 2026-2036
  • Figure 91: Middle East and Africa Market Attractiveness Analysis by Application
  • Figure 92: Global Market - Tier Structure Analysis
  • Figure 93: Global Market - Company Share Analysis

Frequently Asked Questions

How big is the Animal Model Market in 2026?

FMI estimates the market at USD 2.1 billion in 2026, up from USD 2.0 billion in 2025. It is projected to reach USD 3.8 billion by 2036 at a 6.1% CAGR.

Which species leads the Animal Model Market in 2026?

Mice lead by species with 65.0% in 2026. All other species together hold 35.0%.

Which application and end user lead in 2026?

Drug Discovery/Development holds 55.0% by application. Academic & Research Institutions hold 38.8% by end user in FMI's 2026 assessment.

Which country is forecast to grow fastest through 2036?

The United States has the highest forecast CAGR at 7.5% during 2026 to 2036, followed by Japan at 6.5%. These are FMI forecasts and are not rates reported by the cited public bodies.

How do policies on alternative methods affect animal model demand?

They remove specific tests first. The UK plans to end regulatory skin and eye irritation tests on animals by the end of 2026 and to reduce pharmacokinetic studies in dogs and primates by 2030 [20].

Preview the report firsthand - request a free sample

Get Sample

Get the brochure for pricing and purchase details.

Future Market Insights

Animal Model Market